Centessa Pharmaceuticals (NASDAQ:CNTA) Issues Quarterly Earnings Results

Centessa Pharmaceuticals (NASDAQ:CNTA) issued its quarterly earnings results on Tuesday. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05, Zacks reports.

Centessa Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ:CNTA opened at $17.50 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.29 and a current ratio of 21.52. Centessa Pharmaceuticals has a 52-week low of $5.58 and a 52-week high of $18.74. The business’s 50 day simple moving average is $15.87 and its two-hundred day simple moving average is $12.07. The firm has a market cap of $1.98 billion, a P/E ratio of -11.44 and a beta of 1.47.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total transaction of $2,891,000.00. Following the transaction, the chief executive officer now owns 776,924 shares of the company’s stock, valued at $12,834,784.48. The trade was a 18.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the sale, the insider now owns 241,171 shares of the company’s stock, valued at $2,935,051.07. This trade represents a 4.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 325,031 shares of company stock valued at $5,213,043 over the last ninety days. 11.59% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective on the stock. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, Oppenheimer reissued an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.